【从617美元到350美元:CVS给减肥药开出“盈亏平衡价”,称药企仍能赚钱】智通财经APP获悉,一项针对保险索赔数据的分析发现,如果将用于减重和糖尿病的GLP-1类药物定价在每月350美元以下,支付方——如雇主和计划发起人——将因相关医疗服务使用量下降而实现净节省。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.